GO:0047748 cholestanetetraol 26-dehydrogenase activity

GO:0047748 cholestanetetraol 26-dehydrogenase activity is a molecular function that catalyzes a specific step in bile acid biosynthesis, converting 5beta-cholestane-3alpha,7alpha,12alpha-triol to (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate through an adrenodoxin-dependent oxidation. This activity is essential for the proper side-chain oxidation of cholesterol derivatives, a process required for the production of mature bile acids. The enzyme responsible for this activity in humans has been studied in the context of liver alcohol dehydrogenase, which exhibits dual specificity for both alcohol and cholestanetetrol substrates. Understanding this activity is important for researchers investigating lipid metabolism, liver physiology, and metabolic disorders. The reaction consumes molecular oxygen and reduced adrenodoxin while producing water and oxidized adrenodoxin, highlighting its integration with mitochondrial electron transport systems. As a molecular function annotation, GO:0047748 provides a precise biochemical definition that enables functional genomics and enzyme engineering studies.

In our own words, GO:0047748 cholestanetetraol 26-dehydrogenase activity describes the catalytic conversion of 5beta-cholestane-3alpha,7alpha,12alpha-triol into (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate. This reaction requires five protons, three molecules of molecular oxygen, and six reduced adrenodoxin molecules, yielding four water molecules and six oxidized adrenodoxin molecules. The activity is synonymous with 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol dehydrogenase and TEHC-NAD oxidoreductase activity, reflecting its role in steroid side-chain oxidation.

GO:0047748 cholestanetetraol 26-dehydrogenase activity is critical for bile acid biosynthesis, a fundamental metabolic pathway that enables the absorption of dietary fats and fat-soluble vitamins. The enzyme responsible for this activity, human liver alcohol dehydrogenase, has been shown to catalyze the dehydrogenation of 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol, linking alcohol metabolism to sterol side-chain oxidation. Defects in bile acid synthesis can lead to cholestatic liver disease, neurological symptoms, and fat malabsorption. Therefore, understanding this activity at the molecular level provides insights into metabolic regulation and potential therapeutic targets.

The following genes and proteins are associated with cholestanetetraol 26-dehydrogenase activity or related bile acid synthesis pathways.

The activity of cholestanetetraol 26-dehydrogenase is regulated at multiple levels. Human liver alcohol dehydrogenase, which can catalyze this reaction, is subject to transcriptional regulation by factors such as C/EBP and HNF4. Additionally, the availability of adrenodoxin and its redox state influence the reaction rate. Bile acid synthesis is feedback-inhibited by farnesoid X receptor (FXR) signaling, which downregulates CYP7A1 and other enzymes. However, direct regulation of the dehydrogenase step by nuclear receptors or post-translational modifications remains to be fully elucidated.

Impaired bile acid synthesis due to defects in side-chain oxidation can lead to cholestasis, characterized by bile flow obstruction and liver damage. Although direct mutations in the dehydrogenase activity are not well documented, alcohol dehydrogenase variants have been associated with altered bile acid profiles. Understanding this activity may reveal new therapeutic targets for cholestatic disorders.

Alterations in bile acid synthesis contribute to metabolic syndrome, obesity, and diabetes. The dehydrogenase activity, by influencing bile acid pool composition, may affect glucose and lipid homeostasis. Studies on alcohol dehydrogenase substrate specificity provide a foundation for investigating these links.

Bile acid synthesis defects often present with neurological symptoms due to accumulation of toxic intermediates. The 26-oate product of this reaction is a precursor to neuroactive steroids. Dysregulation of the dehydrogenase step could potentially impact brain function, though direct evidence is limited.

Recombinant human liver alcohol dehydrogenase can be assayed for cholestanetetrol dehydrogenase activity using spectrophotometric methods that monitor NADH production or adrenodoxin reduction. Kinetic parameters such as Km and Vmax provide insights into substrate affinity and catalytic efficiency.

CRISPR-Cas9 knockout of candidate genes such as ADH1B in liver cell lines allows researchers to assess the contribution of specific enzymes to cholestanetetrol oxidation. Metabolomic profiling by LC-MS can quantify bile acid intermediates and products.

RNA-seq and quantitative proteomics can reveal co-expression patterns of ADH1B with bile acid synthesis enzymes. These approaches help identify regulatory networks and potential compensatory pathways.

Mouse models with liver-specific deletions of ADH1B or related genes enable in vivo studies of bile acid metabolism. Bile can be collected for analysis of bile acid composition by HPLC-MS.

Researchers studying cholestanetetraol 26-dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in bile acid synthesis or metabolic regulation. EDITGENE provides comprehensive CRISPR services to accelerate this research.

GO:0047748 cholestanetetraol 26-dehydrogenase activity represents a key enzymatic step in bile acid biosynthesis, with human liver alcohol dehydrogenase serving as a notable catalyst. Understanding its mechanism, regulation, and role in disease provides a foundation for metabolic research and therapeutic development. CRISPR-based models offer powerful tools to dissect this activity and its contribution to liver physiology.